OGIVRI 440 mg subst sèche c solv flac perf 1 pce

7680674700012 CH-67470 L01FD01 07.16.1.

Active substances:

OGIVRI 440 mg subst sèche c solv flac perf 1 pce
OGIVRI 440 mg subst sèche c solv flac perf 1 pce
OGIVRI 440 mg subst sèche c solv flac perf 1 pce
1 / 3
google

Details

Product number
6747001
CPT
-
Packaging group
1
Unit
Durchstechflasche(n)
Composition
Praeparatio cryodesiccata: trastuzumabum 440 mg, histidinum, histidini hydrochloridum monohydricum, macrogolum 3350, sorbitolum 337.9 mg, acidum hydrochloridum, natrii hydroxidum corresp. natrium 0.18 mg, pro vitro. Solvens: alcohol benzylicus 231 mg, aqua ad iniectabile q.s. ad solutionem 20 ml, solutio reconstituta 1 ml corresp. trastuzumabum 21 mg.

Articles (1)

Ogivri 440 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
1
View

Official Swissmedic V2 data

Additional information from the official database

Detailed composition

Substance Quantity Type Category
alcohol benzylicus
231.0 MG Substance Konservierungsstoff (Conservateur)
trastuzumabum
440.0 MG Substance Wirkstoff (Principe actif)
aqua ad iniectabile
- Substance HNIDK
histidinum
- Substance HNIDK
histidini hydrochloridum monohydricum
- Substance HNIDK
macrogolum 3350
- Substance HNIDK
trastuzumabum
21.0 MG Substance Wirkstoff (Principe actif)
sorbitolum
337.9 MG Substance HBESI
acidum hydrochloridum
- Substance HNIDK
natrii hydroxidum
- Substance HNIDK
natrium
0.18 MG Substance HBESI

Reimbursement information

Public price
CHF 1469.00
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/09/2020

Authorization holder

Medius AG

4132 Muttenz

Authorization information

Swissmedic authorization number
67470
Drug name
Ogivri 440 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
Galenic form
LSPA
ATC Code
L01FD01
Authorization status
Z
Dispensation category
A
First authorization
02/04/2020
Authorization expiration date
31/12/9999
IT number
07.16.1.
Domain
Human medicine
Field of application
Mammakarzinom, Magenkarzinom oder Karzinom des gastroösophagealen Übergangs

Packaging details

Description (FR)
OGIVRI 440 mg subst sèche c solv flac perf 1 pce
Description (DE)
OGIVRI 440 mg Trockensub c Solv Durchstf 1 Stk
Market launch
02/04/2020
Narcotic (BTM)
No
Buy us a coffee Explore the data